S Conroy1, V Peden. 1. Academic Division of Child Health, University of Nottingham, Derbyshire Children's Hospital, Uttoxeter Road, Derby DE22 3NE, UK.
Abstract
BACKGROUND: The management of pain in children has advanced enormously in recent years. Pharmacological treatment of pain is complicated however, by the widespread use of unlicensed and off label medicines in the paediatric population, leading to everyday practical problems. This study aimed to document the incidence and nature of unlicensed and off label analgesic agents in children. METHODS: Data regarding analgesic use were collected prospectively over a 4-week period from two wards. The data were analysed to determine whether the drug use was licensed, unlicensed or off label. RESULTS: Seven hundred and fifteen prescription episodes were analysed. Some 480 of these (67%) were licensed; 235 were licensed medicines used in an off label manner (33%). No medicines were unlicensed. Paracetamol was the most common analgesic used. CONCLUSION: Issues regarding the use of off label drugs in children at risk of pain are discussed. Suggestions are made regarding the way forward for the future.
BACKGROUND: The management of pain in children has advanced enormously in recent years. Pharmacological treatment of pain is complicated however, by the widespread use of unlicensed and off label medicines in the paediatric population, leading to everyday practical problems. This study aimed to document the incidence and nature of unlicensed and off label analgesic agents in children. METHODS: Data regarding analgesic use were collected prospectively over a 4-week period from two wards. The data were analysed to determine whether the drug use was licensed, unlicensed or off label. RESULTS: Seven hundred and fifteen prescription episodes were analysed. Some 480 of these (67%) were licensed; 235 were licensed medicines used in an off label manner (33%). No medicines were unlicensed. Paracetamol was the most common analgesic used. CONCLUSION: Issues regarding the use of off label drugs in children at risk of pain are discussed. Suggestions are made regarding the way forward for the future.
Authors: M Bajcetic; M Jelisavcic; J Mitrovic; N Divac; S Simeunovic; R Samardzic; R Gorodischer Journal: Eur J Clin Pharmacol Date: 2005-09-08 Impact factor: 2.953
Authors: Mei-Nga Smit-Wu; Désiree M W G Moonen-Delarue; Manon J N L Benders; Wim Brussel; Hans Zondervan; Frank Brus Journal: Eur J Pediatr Date: 2006-03-04 Impact factor: 3.183
Authors: Joseph F Standing; Kuan Ooi; Simon Keady; Richard F Howard; Imogen Savage; Ian C K Wong Journal: Br J Clin Pharmacol Date: 2009-08 Impact factor: 4.335
Authors: Valentina Franco; Maria Paola Canevini; Giuseppe Capovilla; Giovambattista De Sarro; Carlo Andrea Galimberti; Giuliana Gatti; Renzo Guerrini; Angela La Neve; Eleonora Rosati; Luigi Maria Specchio; Salvatore Striano; Paolo Tinuper; Emilio Perucca Journal: CNS Drugs Date: 2014-10 Impact factor: 5.749
Authors: Ammar Kazouini; Baba S Mohammed; Colin R Simpson; Peter J Helms; James S McLay Journal: Br J Clin Pharmacol Date: 2011-09 Impact factor: 4.335